Top

European Journal of Clinical Microbiology & Infectious Diseases

Published in:

01-07-2013 | Review

Recent changes in bacteremia in patients with cancer: a systematic review of epidemiology and antibiotic resistance

Authors: E. Montassier, E. Batard, T. Gastinne, G. Potel, M. F. de La Cochetière

Published in: European Journal of Clinical Microbiology & Infectious Diseases | Issue 7/2013

Abstract

Bacteremia remains a major cause of life-threatening complication in patients with cancer. Significant changes in the spectrum of microorganisms isolated from blood culture have been reported in cancer patients over the past years. The aim of our systematic review was to inventory the recent trends in epidemiology and antibiotic resistance of microorganisms causing bacteremia in cancer patients. Data for this review was identified by searches of Medline, Scopus and Cochrane Library for indexed articles and abstracts published in English since 2008. The principal search terms were: “antimicrobial resistance”, “bacteremia”, “bacterial epidemiology”, “bloodstream infection”, “cancer patients”, “carbapenem resistance”, “Escherichia coli resistance”, “extended-spectrum β-lactamase producing E. coli”, “febrile neutropenia”, “fluoroquinolone resistance”, “neutropenic cancer patient”, “vancomycin-resistant Enterococcus”, and “multidrug resistance”. Boolean operators (NOT, AND, OR) were also used in succession to narrow and widen the search. Altogether, 27 articles were selected to be analyzed in the review. We found that Gram-negative bacteria were the most frequent pathogen isolated, particularly in studies with minimal use of antibiotic prophylaxis. Another important trend is the extensive emergence of antimicrobial-resistant strains associated with increased risk of morbidity, mortality and cost. This increasing incidence of antibiotic resistance has been reported in Gram-negative bacteria as well as in Gram-positive bacteria. This exhaustive review, reporting the recent findings in epidemiology and antibiotic resistance of bacteremia in cancer patients, highlights the necessity of local continuous surveillance of bacteremia and stringent enforcement of antibiotic stewardship programs in cancer patients.

Klastersky J (2004) Management of fever in neutropenic patients with different risks of complications. Clin Infect Dis 39:S327CrossRef

Freifeld AG, Bow EJ, Sepkowitz KA, Boeckh MJ, Ito JI, Mullen CA, Raad II, Rolston KV, Young JA, Wingard JR, Infectious Diseases Society of America (2011) Clinical practice guideline for the use of antimicrobial agents in neutropenic patients with cancer: 2010 Update by the Infectious Diseases Society of America. Clin Infect Dis 52(4):427–431CrossRefPubMed

Arnold RJ, Gabrail N, Rat M, Kim R, Sung JC, Zhou Y (2005) Clinical implications of chemotherapy induced diarrhea in patients with cancer. J Support Oncol 3:227–232PubMed

van Vliet MJ, Harmsen HJ, de Bont ES, Tissing WJ (2010) The role of intestinal microbiota in the development and severity of chemotherapy-induced Mucositis. Plos Pathol 27:e1000879CrossRef

Jones RN (1999) Contemporary antimicrobial susceptibility pattern of bacterial pathogens commonly associated with febrile patients with neutropenia. Clin Infect Dis 29:495–502CrossRefPubMed

Irfan S, Idrees F, Mehraj V, Habib F, Adil S, Hasan R (2008) Emergence of Carbapenem resistant Gram negative and vancomycin resistant Gram positive organisms in bacteremic isolates of febrile neutropenic patients: a descriptive study. BMC Infect Dis 8:80CrossRefPubMed

Ramphal R (2004) Changes in the etiology of bacteremia in febrile neutropenic patients and the susceptibilities of the currently isolated pathogens. Clin Infect Dis 39:S25–S31CrossRefPubMed

Zinner SH (1999) Changing epidemiology of infections in patients with neutropenia and cancer: emphasis on gram-positive and resistant bacteria. Clin Infect Dis 29:490–494CrossRefPubMed

Wisplinghoff H, Seifert H, Wenzel RP, Edmond MB (2003) Current trends in the epidemiology of nosocomial bloodstream infections in patients with hematological malignancies and solid neoplasms in hospitals in the United States. Clin Infect Dis 36:1103–1110CrossRefPubMed

10.

Sharma A, Lokeshwar N (2005) Febrile neutropenia in haematological malignancies. J Postgrad Med 51:42–48

11.

Wu HS, Kuo SC, Lee YT, Yang YS, Cheng SS, Chen TL, Fung CP (2012) Clinical characteristics and prognostic factors of Acinetobacter nosocomialis bacteraemia in patients with solid tumours. Clin Microbiol Infect 18(9):E373–E376CrossRefPubMed

12.

Kang CI, Kim SH, Park WB, Lee KD, Kim HB, Kim EC, Oh MD, Choe KW (2004) Bloodstream infections due to extended spectrum factors for mortality and treatment outcome, with special emphasis on antimicrobial therapy. Antimicrob Agents Chemother 48:4574–4581CrossRefPubMed

13.

Kim YK, Pai H, Lee HJ, Park SE, Choi EH, Kim J, Kim JH, Kim EC (2002) Bloodstream infections by extended-spectrum β-lactamase producing Escherichia coli and Klebsiella pneumoniae in children: epidemiology and clinical outcome. Antimicrob Agents Chemother 46(1481):1491

14.

Cattaneo C, Antoniazzi F, Casari S, Ravizzola G, Gelmi M, Pagani C, D’Adda M, Morello E, Re A, Borlenghi E, Manca N, Rossi G (2012) P. aeruginosa bloodstream infections among hematological patients: an old or new question? Ann Hematol 91(8):1299–1304CrossRefPubMed

15.

Kjellander C, Björkholm M, Cherif H, Kalin M, Giske CG (2012) Hematological: low all-cause mortality and low occurrence of antimicrobial resistance in hematological patients with bacteremia receiving no antibacterial prophylaxis: a single-center study. Eur J Haematol 88(5):422–430CrossRefPubMed

16.

Chong Y, Yakushiji H, Ito Y, Kamimura T (2011) Clinical impact of fluoroquinolone prophylaxis in neutropenic patients with hematological malignancies. Int J Infect Dis 15(4):e277–e281CrossRefPubMed

17.

Saghir S, Faiz M, Saleem M, Younus A, Aziz H (2009) Characterization and anti-microbial susceptibility of Gram-negative bacteria isolated from bloodstream infections of cancer patients on chemotherapy in Pakistan. Indian J Med 27:341–347

18.

Kang CI, Song JH, Chung DR, Peck KR, Yeom JS, Son JS, Wi YM, on behalf of the Korean Network for Study on Infectious Diseases (KONSID) (2012) Bloodstream infections in adult patients with cancer: clinical features and pathogenic significance of Staphylococcus aureus bacteremia. Support Care Cancer 20(10):2371–2378

19.

Lanoix JP, Pluquet E, Lescure FX, Bentayeb H, Lecuyer E, Boutemy M, Dumont P, Jounieaux V, Schmit JL, Dayen C, Douadi Y (2011) Bacterial infection profiles in lung cancer patients with febrile neutropenia. BMC Infect Dis 11:183CrossRefPubMed

20.

Gudiol C, Bodro M, Simonetti A, Tubau F, González-Barca E, Cisnal M, Domingo-Domenech E, Jiménez L, Carratalà J (2012) Changing aetiology, clinical features, antimicrobial resistance, and outcomes of bloodstream infection in neutropenic cancer patients. Clin Microbiol Infect. doi:10.1111/j.1469-0691.2012.03879

21.

Trecarichi EM, Tumbarello M, Spanu T, Caira M, Fianchi L, Chiusolo P, Fadda G, Leone G, Cauda R, Pagano L (2009) Incidence and clinical impact of extended-spectrum-beta-lactamase (ESBL) production and fluoroquinolone resistance in bloodstream infections caused by Escherichia coli in patients with hematological malignancies. J Infect 58(4):299–307CrossRefPubMed

22.

Bhusal Y, Mihu CN, Tarrand JJ, Rolston KV (2011) Incidence of fluoroquinolone-resistant and extended-spectrum β-lactamase-producing Escherichia coli at a comprehensive cancer center in the United States. Chemotherapy 57(4):335–338CrossRefPubMed

23.

Jacobson K, Rolston K, Elting L, LeBlanc B, Whimbey E, Ho DH (1999) Susceptibility surveillance among Gram-negative bacilli at a cancer center. Chemotherapy 45:325–334CrossRefPubMed

24.

Mihu CN, Rhomberg PR, Jones RN, Coyle E, Prince RA, Rolston KV (2010) Escherichia coli resistance to quinolones at a comprehensive cancer center. Diagn Microbiol Infect Dis 67(3):266–269CrossRefPubMed

25.

Bell JM, Turnidge JD, Gales AC, Pfaller MA, Jones RN, Sentry APAC Study Group (2002) Prevalence of extended-spectrum beta-lactamase (ESBL)—producing clinical isolates in the Asia-Pacific region and South Africa: regional results from SENTRY Antimicrobial Surveillance Program (1998–99). Diagn Microbiol Infect Dis 42:193–198CrossRefPubMed

26.

Gulay Z, Thomson CJ, Yulug N, Amyes SG (2000) High prevalence of extended spectrum beta-lactamase production among Klebsiella pneumoniae strains isolated at a university hospital in Turkey. J Chemother 12:145–152PubMed

27.

Vahaboglu H, Ozturk R, Aygun G, Coşkunkan F, Yaman A, Kaygusuz A, Leblebicioglu H, Balik I, Aydin K, Otkun M (1997) Widespread detection of PER-1–type extended-spectrum beta-lactamases among nosocomial Acinetobacter and Pseudomonas aeruginosa isolates in Turkey: a nationwide multicenter study. Antimicrob Agents Chemother 41:2265–2269PubMed

28.

Arnan M, Gudiol C, Calatayud L, Liñares J, Dominguez MA, Batlle M, Ribera JM, Carratalà J, Gudiol F (2011) Risk factors for, and clinical relevance of, faecal extended-spectrum β-lactamase producing Escherichia coli (ESBL-EC) carriage in neutropenic patients with haematological malignancies. Eur J Clin Microbiol Infect Dis 30(3):355–360CrossRefPubMed

29.

Gudiol C, Calatayud L, Garcia-Vidal C, Lora-Tamayo J, Cisnal M, Duarte R, Arnan M, Marin M, Carratalà J, Gudiol F (2010) Bacteraemia due to extended-spectrum beta-lactamase-producing Escherichia coli (ESBL-EC) in cancer patients: clinical features, risk factors, molecular epidemiology and outcome. J Antimicrob Chemother 65(2):333–341CrossRefPubMed

30.

Liss BJ, Vehreschild JJ, Cornely OA, Hallek M, Fätkenheuer G, Wisplinghoff H, Seifert H, Vehreschild MJ (2012) Intestinal colonisation and blood stream infections due to vancomycin-resistant enterococci (VRE) and extended-spectrum beta-lactamase-producing Enterobacteriaceae (ESBLE) in patients with haematological and oncological malignancies. Infection 40(6):613–619CrossRefPubMed

31.

Kang CI, Chung DR, Ko KS, Peck KR, Song JH, Korean Network for Study of Infectious Diseases (2012) Risk factors for infection and treatment outcome of extended-spectrum β-lactamase-producing Escherichia coli and Klebsiella pneumoniae bacteremia in patients with hematologic malignancy. Ann Hematol 91(1):115–121CrossRefPubMed

32.

Almyroudis NG, Fuller A, Jakubowski A, Sepkowitz K, Jaffe D, Small TN, Kiehn TE, Pamer E, Papanicolaou GA (2005) Pre- and postengraftment bloodstream infection rates and associated mortality in allogeneic hematopoietic stem cell transplant recipients. Transpl Infect Dis 7:11–17CrossRefPubMed

33.

Avery R, Kalaycio M, Pohlman B, Sobecks R, Kuczkowski E, Andresen S, Mossad S, Shamp J, Curtis J, Kosar J, Sands K, Serafin M, Bolwell B (2005) Early vancomycin resistant enterococcus (VRE) bacteremia after allogeneic bone marrow transplantation is associated with a rapidly deteriorating clinical course. Bone Marrow Transplant 35:497–499CrossRefPubMed

34.

Kapur D, Dorsky D, Feingold JM, Bona RD, Edwards RL, Aslanzadeh J, Tutschka PJ, Bilgrami S (2000) Incidence and outcome of vancomycin-resistant enterococcal bacteremia following autologous peripheral blood stem cell transplantation. Bone Marrow Transplant 25:147–152CrossRefPubMed

35.

Weinstock DM, Conlon M, Iovino C, Aubrey T, Gudiol C, Riedel E, Young JW, Kiehn TE, Zuccotti G (2007) Colonization, bloodstream infection, and mortality caused by vancomycin-resistant enterococcus early after allogeneic hematopoietic stem cell transplant. Biol Blood Marrow Transplant 13:615–621CrossRefPubMed

36.

Zirakzadeh A, Gastineau DA, Mandrekar JN, Burke JP, Johnston BP, Patel R (2008) Vancomycin-resistant enterococcal colonization appears associated with increased mortality among allogeneic hematopoietic stem cell transplant recipients. Bone Marrow Transplant 41:385–392CrossRefPubMed

37.

Kamboj M, Chung D, Seo SK, Pamer EG, Sepkowitz KA, Jakubowski AA, Papanicolaou G (2010) The changing epidemiology of vancomycin-resistant Enterococcus (VRE) bacteremia in allogeneic hematopoietic stem cell transplant (HSCT) recipients. Biol Blood Marrow Transplant 16(11):1576–1581CrossRefPubMed

38.

Bossaer JB, Hall PD, Garrett-Mayer E (2010) Incidence of vancomycin-resistant enterococci (VRE) infection in high-risk febrile neutropenic patients colonized with VRE. Support Care Cancer 19(2):231–237CrossRefPubMed

39.

Quilty S, Kwok G, Hajkowicz K, Currie B (2009) High incidence of methicillin resistant Staphylococcus aureus sepsis and death in patients with febrile neutropenia at Royal Darwin Hospital. Intern Med J 39:557–559CrossRefPubMed

40.

Prabhash K, Medhekar A, Ghadyalpatil N, Noronha V, Biswas S, Kurkure P, Nair R, Kelkar R (2010) Blood stream infections in cancer patients: a single center experience of isolates and sensitivity pattern. Indian J Cancer 47:184–188CrossRefPubMed

41.

Karim M, Khan W, Farooqi B, Malik I (1991) Bacterial isolates in neutropenic febrile patients. J Pak Med Assoc 48:364–367

42.

Rangaraj G, Granwehr BP, Jiang Y, Hachem R, Raad I (2010) Perils of quinolone exposure in cancer patients: breakthrough bacteremia with multidrug-resistant organisms. Cancer 116(4):967–973CrossRefPubMed

43.

Gudiol C, Tubau F, Calatayud L, Garcia-Vidal C, Cisnal M, Sánchez-Ortega I, Duarte R, Calvo M, Carratalà J (2011) Bacteraemia due to multidrug-resistant Gram-negative bacilli in cancer patients: risk factors, antibiotic therapy and outcomes. J Antimicrob Chemother 66(3):657–663CrossRefPubMed

44.

Trecarichi EM, Tumbarello M, Caira M, Candoni A, Cattaneo C, Pastore D, Fanci R, Nosari A, Vianelli N, Busca A, Spadea A, Pagano L (2011) Multidrug resistant Pseudomonas aeruginosa bloodstream infection in adult patients with hematologic malignancies. Haematologica 96(1):e1–e3CrossRefPubMed

45.

Klastersky J, Ameye L, Maertens J, Georgala A, Muanza F, Aoun M, Ferrant A, Rapoport B, Rolston K, Paesmans M (2007) Bacteraemia in febrile neutropenic cancer patients. Int J Antimicrob Agents S1:S51–S59CrossRef

46.

Cruciani M, Rampazzo R, Malena M, Lazzarini L, Todeschini G, Messori A, Concia E (1996) Prophylaxis with fluoroquinolones for bacterial infections in neutropenic patients: a meta-analysis. Clin Infect Dis 23:795–805CrossRefPubMed

47.

Bow EJ (2011) Fluoroquinolones, antimicrobial resistance and neutropenic cancer patients. Curr Opin Infect Dis 24(6):545–553CrossRefPubMed

48.

CLSI (2008) Performance standards for antimicrobial susceptibility testing; eighteenth informational supplement. CLSI document M100-S18. Enterobacteriaceae M7MIC. Clinical and Laboratory Standards Institute, Wayne, PA, pp 98–101

49.

Saito T, Yoshioka S, Iinuma Y, Takakura S, Fujihara N, Ichinohe T, Ishikawa T, Uchiyama T, Ichiyama S (2008) Effects on spectrum and susceptibility patterns of isolates causing bloodstream infection by restriction of fluoroquinolone prophylaxis in a hematology–oncology unit. Eur J Clin Microbiol Infect Dis 27:209–216CrossRefPubMed

50.

Engels EA, Ellis CA, Supran SE, Schmid CH, Barza M, Schenkein DP, Koc Y, Miller KB, Wong JB (1999) Early infection in bone marrow transplantation: quantitative study of clinical factors that affect risk. Clin Infect Dis 28:256–266CrossRefPubMed

51.

Ghosh I, Raina V, Kumar L, Sharma A, Bakhshi S, Thulkar S, Kapil A (2012) Profile of infections and outcome in high-risk febrile neutropenia: experience from a tertiary care cancer center in India. Med Oncol 29(2):1354–1360CrossRefPubMed

52.

Richard P, Delangi MH, Raffi F, Espaze E, Richet H (2001) Impact of fluoroquinolone administration on the emergence of fluoroquinolone-resistant, gram-negative bacilli from gastrointestinal flora. Clin Infect Dis 32:162–166CrossRefPubMed

53.

Cheong HJ, Yoo CW, Sohn JW, Kim WJ, Kim MJ, Park SC (2001) Bacteremia due to quinolone-resistant Escherichia coli in a teaching hospital in South Korea. Clin Infect Dis 33:48–53CrossRefPubMed

54.

McDonald LC, Chen FJ, Lo HJ, Yin HC, Lu PL, Huang CH, Chen P, Lauderdale TL, Ho M (2001) Emergence of reduced susceptibility and resistance to fluoroquinolones in Escherichia coli in Taiwan and contributions of distinct selective pressures. Antimicrob Agents Chemother 45:3084–3089CrossRefPubMed

55.

Lodise TP Jr, Patel N, Kwa A, Graves J, Furuno JP, Graffunder E, Lomaestro B, McGregor JC (2007) Predictors of 30-day mortality among patients with Pseudomonas aeruginosa bloodstream infections: impact of delayed appropriate antibiotic selection. Antimicrob Agents Chemother 51(10):3510–3515CrossRefPubMed

56.

Giske CG, Monnet DL, Cars O, Carmeli Y, ReAct-Action on Antibiotic Resistance (2008) Clinical and economic impact of common multidrug-resistant gram-negative bacilli. Antimicrob Agents Chemother 52(3):813–821CrossRefPubMed

57.

Caselli D, Cesaro S, Ziino O, Zanazzo G, Manicone R, Livadiotti S, Cellini M, Frenos S, Milano GM, Cappelli B, Licciardello M, Beretta C, Aricò M, Castagnola E, Infection Study Group of the Associazione Italiana Ematologia Oncologia Pediatrica (AIEOP) (2010) Multidrug resistant Pseudomonas aeruginosa infection in children undergoing chemotherapy and hematopoietic stem cell transplantation. Haematologica 95(9):1612–1615CrossRefPubMed

Title: Recent changes in bacteremia in patients with cancer: a systematic review of epidemiology and antibiotic resistance
Authors: E. Montassier
E. Batard
T. Gastinne
G. Potel
M. F. de La Cochetière
Publication date: 01-07-2013
Publisher: Springer-Verlag
Published in: European Journal of Clinical Microbiology & Infectious Diseases / Issue 7/2013
Print ISSN: 0934-9723
Electronic ISSN: 1435-4373
DOI: https://doi.org/10.1007/s10096-013-1819-7

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 7/2013

Characteristics of Yersinia enterocolitica biotype 1A strains isolated from patients and asymptomatic carriers

A positive interaction between inhibitors of protein synthesis and cefepime in the fight against methicillin-resistant Staphylococcus aureus

Erratum to: Prevalence and distribution of Helicobacter pylori cagA and vacA genotypes in the Moroccan population with gastric disease

Assessment of the significance of respiratory culture of Aspergillus in the non-neutropenic patient. A critique of published diagnostic criteria

DNA bacterial load in children with bacteremic pneumococcal community-acquired pneumonia

Impact of a computerized alert system for bacteremia notification on the appropriate antibiotic treatment of Staphylococcus aureus bloodstream infections

Keynote webinar | Spotlight on medication adherence

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

At a glance: The STEP trials